Made in Europe – assessing the feasibility of reshoring active pharmaceutical ingredient production to Europe
While reshoring may increase the resilience of the supply chain, it is rather a supportive measure for supply chain stability than a standalone solution to prevent medicine shortages.
Authors
- Caroline Steigenberger (ORCID: https://orcid.org/0000-0003-0713-2623)
- Sabine Vogler
- Verena Knoll (ORCID: https://orcid.org/0009-0001-2685-689X)
- Stefan Fischer (ORCID: https://orcid.org/0000-0003-2353-4497)
Institutions
- Gesundheit Österreich (AT)
Publication Details
- Journal
- Health Policy
- Published
- 2026-01-25
- DOI
- https://doi.org/10.1016/j.healthpol.2026.105566
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00